A phase 2 trial is currently underway to compare PVSRIPO (Lerapolturev) as an intralesional monotherapy with a combination of PVSRIPO and anti-PD-1 therapy for unresectable anti-PD-1/L1 refractory stage III-IVM1b melanoma (NCT04577807). Here, PDCD1 is linked to melanoma.